ELAN vs. BPMC, CYTK, ITCI, JAZZ, IONS, CERE, ASND, APLS, OGN, and BBIO
Should you be buying Elanco Animal Health stock or one of its competitors? The main competitors of Elanco Animal Health include Blueprint Medicines (BPMC), Cytokinetics (CYTK), Intra-Cellular Therapies (ITCI), Jazz Pharmaceuticals (JAZZ), Ionis Pharmaceuticals (IONS), Cerevel Therapeutics (CERE), Ascendis Pharma A/S (ASND), Apellis Pharmaceuticals (APLS), Organon & Co. (OGN), and BridgeBio Pharma (BBIO). These companies are all part of the "pharmaceutical preparations" industry.
Elanco Animal Health (NYSE:ELAN) and Blueprint Medicines (NASDAQ:BPMC) are both mid-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their risk, institutional ownership, media sentiment, analyst recommendations, earnings, profitability, dividends, valuation and community ranking.
Elanco Animal Health has a net margin of -27.87% compared to Blueprint Medicines' net margin of -102.15%. Elanco Animal Health's return on equity of 6.44% beat Blueprint Medicines' return on equity.
Blueprint Medicines has lower revenue, but higher earnings than Elanco Animal Health. Blueprint Medicines is trading at a lower price-to-earnings ratio than Elanco Animal Health, indicating that it is currently the more affordable of the two stocks.
Elanco Animal Health has a beta of 1.34, indicating that its stock price is 34% more volatile than the S&P 500. Comparatively, Blueprint Medicines has a beta of 0.65, indicating that its stock price is 35% less volatile than the S&P 500.
Blueprint Medicines received 387 more outperform votes than Elanco Animal Health when rated by MarketBeat users. Likewise, 67.80% of users gave Blueprint Medicines an outperform vote while only 54.36% of users gave Elanco Animal Health an outperform vote.
Elanco Animal Health presently has a consensus target price of $17.29, indicating a potential upside of 0.47%. Blueprint Medicines has a consensus target price of $100.31, indicating a potential downside of 7.41%. Given Elanco Animal Health's stronger consensus rating and higher possible upside, equities analysts clearly believe Elanco Animal Health is more favorable than Blueprint Medicines.
In the previous week, Blueprint Medicines had 27 more articles in the media than Elanco Animal Health. MarketBeat recorded 52 mentions for Blueprint Medicines and 25 mentions for Elanco Animal Health. Elanco Animal Health's average media sentiment score of 0.68 beat Blueprint Medicines' score of 0.55 indicating that Elanco Animal Health is being referred to more favorably in the media.
97.5% of Elanco Animal Health shares are owned by institutional investors. 0.6% of Elanco Animal Health shares are owned by company insiders. Comparatively, 3.9% of Blueprint Medicines shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.
Summary
Elanco Animal Health beats Blueprint Medicines on 11 of the 19 factors compared between the two stocks.
Get Elanco Animal Health News Delivered to You Automatically
Sign up to receive the latest news and ratings for ELAN and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding ELAN and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NYSE and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Elanco Animal Health Competitors List
Related Companies and Tools
